FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML

December 19, 2017 – The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), based on findings from the phase III BFORE trial. In the open-label study, the major molecular response (MMR) at 12 months was 47.2% with bosutinib (95% CI, 40.9-53.4) compared with 36.9% (95% CI, 30.8-43.0) for imatinib (P = .02). The complete cytogenetic response (CCyR) rate by 12 … (leggi tutto)